AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05643989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic self-expandable metal stent placement
Description: The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
Study NCT04530838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine
Study NCT04530838 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study NCT02762097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: polypectomy
Description: . During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
Study NCT02762097 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline sonography
Description: saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
Study NCT02762097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline sonography
Description: saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
Study NCT02762097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline would be injected into uterine cavity to delineate defects
Study NCT02762097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Normal saline would be injected into uterine cavity to delineate defects
Study NCT05744609 — intervention group
Intervention type: OTHER
Intervention: exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports
Description: epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
Study NCT03020602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03020602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03020602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubidecarenone Injectable Nanosuspension
Description: Given IV
Study NCT04407819 — intervention group
Intervention type: RADIATION
Intervention: WHOLE BODY DXA
Description: Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
Study NCT02927847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
Study NCT02927847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
Study NCT02927847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM Nicotine Research Cigarettes (.03 mg)
Description: For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
Study NCT02927847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPECTRUM Nicotine Research Cigarettes (.03 mg)
Description: For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
Study NCT02927847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
Study NCT02927847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
Study NCT02059993 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: continuous positive airway pressure
Description: mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
Study NCT00463801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT04813250 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ventilation mode setting
Description: Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
Study NCT04813250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation mode setting
Description: Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
Study NCT00495326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine based therapy
Description: * Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)
Study NCT00495326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz based therapy
Description: Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
Study NCT00495326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
Description: * Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase.
Study NCT00495326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
Description: * Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase.
Study NCT02578550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)
Description: A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
Study NCT02578550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir alafenamide FDC
Description: A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
Study NCT02578550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: A single tablet containing darunavir 800 mg will be administered.
Study NCT02578550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: A single table containing cobistat 150 mg will be administered.
Study NCT00519337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid
Description: Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
Study NCT00519337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
Study NCT03673826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 9 cycles 20/36mg/m2 days 1,2,8,9,15,16
Study NCT03673826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
Study NCT03673826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
Study NCT05138978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer
Description: Toothpaste
Study NCT05138978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection
Description: Toothpaste
Study NCT04435899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Multi-modal exercise protocol
Study NCT02624882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive rapid GAS test
Description: If TDR positive, the child will be treated with antibiotics alone:~* Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~* Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months.
Study NCT02624882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative rapid GAS test
Description: Usual care
Study NCT01935986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Study NCT01935986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01775787 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor
Description: Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
Study NCT03215875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fed- 60mg ER Torsemide
Description: 60mg ER Torsemide will be given after high fat, high-calorie meal
Study NCT03215875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasting- 60mg ER Torsemide
Description: 60mg ER Torsemide will be given after overnight fasting
Study NCT03003702 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nonin
Study NCT03003702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin
Study NCT03004768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA
Study NCT01903577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Task Performance
Description: Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
Study NCT01903577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Task Performance
Description: Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
Study NCT04120428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training program
Description: The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
Study NCT04027764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Combined With S1 and Albumin Paclitaxel
Description: Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \\8
Study NCT03211559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: clinical pilates on mat
Study NCT03211559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: clinical pilates on mat
Study NCT03879356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetyl cysteine
Description: effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
Study NCT01208064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Study NCT01208064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01208064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT01208064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study NCT02575378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronimic chemotherapy plus Chinese Traditional Medicine
Description: Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
Study NCT02575378 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronimic chemotherapy
Description: Capecitabine 300mg/m2, twice a day, everyday
Study NCT02809924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based just-in-time training
Description: Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
Study NCT02809924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video training
Description: Video describing endotracheal intubation
Study NCT02164643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutemetamol (18F)
Study NCT02164643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Study NCT01990573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3mg/kg IV methadone HCl
Description: Group I will receive 0.3mg/kg IV methadone HCl
Study NCT01990573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4mg/kg IV methadon HCl
Description: Group II will receive 0.4mg/kg IV methadone HCl.
Study NCT01990573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control no methadone
Description: The control group will not receive methadone.
Study NCT02377492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressins
Description: Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
Study NCT02377492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressins
Description: Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
Study NCT00886366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6714
Description: Oral single doses a-h suspension
Study NCT00886366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single doses suspension
Study NCT00886366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6714
Description: Oral single doses a-d suspension
Study NCT00886366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6714
Description: Oral single doses d and g suspension
Study NCT03970759 — intervention group
Intervention type: DRUG
Intervention: Stannous Fluoride Dentifrice
Description: Experimental stannous fluoride (0.454%) dentifrice
Study NCT03970759 — intervention group
Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing (0.3%) triclosan.
Study NCT03970759 — intervention group
Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study NCT01836146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnligHTN™ Renal Artery Ablation Catheter
Study NCT01409915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagramostim
Description: 5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
Study NCT01409915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline -- placebo comparator
Description: subcutaneous injection
Study NCT02010905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT02010905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02411279 — intervention group
Intervention type: OTHER
Intervention: Equiped group with telemedicine systems
Study NCT01745562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: Reference product
Study NCT01745562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: Test product
Study NCT04933435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaires
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese Chloride
Description: Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy
Description: Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum chemotherapy
Description: Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
Study NCT03989336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
Study NCT01826981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
Study NCT01826981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily